Regentis Biomaterials Ltd. (NYSE American: RGNT): Could GelrinC Become the First Widely Adopted Off-the-Shelf Regenerative Cartilage Repair Platform?
June 4, 2026
Regenerative medicine has long promised to transform patient care, but investors often become most interested when innovative science begins transitioning toward commercial adoption. Regentis Biomaterials (NYSE American: RGNT) is approaching that transition with GelrinC(R), its cartilage regeneration platform targeting a large orthopedic market where treatment alternatives continue to involve meaningful trade-offs. The opportunity is significant. […]
InvestorNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Advances Simplified Cartilage Repair Platform Toward Key Commercial Milestones
May 29, 2026
Regentis Biomaterials Ltd. (NYSE American: RGNT) is advancing GelrinC®, a cell-free hydrogel implant designed to simplify knee cartilage repair through a single-step, approximately 10-minute procedure that may offer an alternative to traditional microfracture and complex cell-based therapies. The company is targeting an estimated $3 billion U.S. market encompassing roughly 470,000 annual knee cartilage repair cases, […]
InvestorNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Targets Major Gap in Knee Cartilage Repair Market with Off-the-Shelf Regenerative Implant
May 28, 2026
Regentis Biomaterials Ltd. (NYSE American: RGNT) is advancing GelrinC(R), a cell-free hydrogel implant designed to repair knee cartilage damage through a single approximately 10-minute procedure, positioning the company to address a major unmet need in orthopedic medicine. While roughly 472,500 arthroscopic knee procedures in the U.S. each year involve cartilage damage, no approved off-the-shelf regenerative […]
Regentis Biomaterials Ltd. (NYSE American: RGNT) Is ‘One to Watch’
May 27, 2026
Regentis Biomaterials (NYSE American: RGNT) is taking aim at a $3 billion U.S. market with what could be the first true off-the-shelf solution for knee cartilage repair—no cells, no delays, no complexity. Its GelrinC(R) platform delivers faster recovery, stronger outcomes, and lower costs vs. outdated procedures, with clinical data showing ~100% greater pain improvement vs. microfracture. […]
Regentis Biomaterials Ltd. (NYSE American: RGNT) and the Off-the-Shelf Opportunity in Knee Cartilage Repair
May 22, 2026
Knee cartilage damage remains one of the most stubborn problems in orthopedic medicine. Unlike many other tissues in the body, articular cartilage has little natural ability to heal because it lacks both direct blood supply and the biological machinery required for meaningful regeneration. For decades, treatment options have reflected that limitation. Microfracture, the long-standing standard […]
InvestorNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Expands European Commercial Strategy Through Humanitas Collaboration
April 16, 2026
Regentis Biomaterials (NYSE American: RGNT) announced a collaboration with Humanitas Research Hospital in Milan, Italy, to support expanding clinical activities and commercial strategy for GelrinC(R) in Europe, where the product has CE Mark approval for knee cartilage repair. The collaboration includes Prof. Elizaveta Kon, an internationally recognized expert in cartilage regeneration and orthopedic innovation, who […]
InvestorNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Advances GelrinC(R) Manufacturing With New Solvent-Free Production Process
March 17, 2026
Regentis Biomaterials (NYSE American: RGNT) announced the development of a new proprietary solvent-free manufacturing process for GelrinC(R), its off-the-shelf hydrogel implant for treating focal articular knee cartilage injuries, that more than quadruples production yield per batch. The company said the new process is designed to improve production economics and gross margins ahead of GelrinC(R)’s planned […]
InvestorNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Reports 2025 Financial Results and Clinical Progress for GelrinC(R)
February 24, 2026
Regentis Biomaterials (NYSE American: RGNT) reported financial results for the year ended Dec. 31, 2025, and provided a corporate and clinical update highlighting progress in its pivotal Phase III study of GelrinC(R) for knee cartilage repair. The company said its strengthened balance sheet, with more than $7 million in cash following its IPO, is expected […]
InvestorNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Appoints Dr. Galit Reske as Chief Medical Officer
February 19, 2026
Regentis Biomaterials (NYSE American: RGNT), a regenerative medicine company focused on tissue repair solutions, today announced the appointment of Dr. Galit Reske, PhD, as chief medical officer. Dr. Reske brings extensive experience in clinical development, regulatory strategy and global clinical operations, including leadership of CartiHeal’s IDE pivotal study for the Agili-C(TM) cartilage repair implant and […]
InvestorNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Expands European Clinical Network to Support GelrinC(R) Commercial Strategy
February 17, 2026
Regentis Biomaterials (NYSE American: RGNT) announced the expansion of its European clinical site network into new markets, including Italy and Eastern Europe, to support ongoing clinical programs and the commercial strategy for GelrinC(R), which has received CE Mark approval for knee cartilage repair. The expanded network includes leading academic and regional medical centers across Italy, […]
InvestorNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Appoints Ori Gon as CFO and Chief Business Officer
February 4, 2026
Regentis Biomaterials (NYSE American: RGNT) announced the appointment of Ori Gon as chief financial officer and chief business officer, effective immediately. Gon will oversee the company’s commercial and business development initiatives, as well as financial strategy, planning and reporting, as Regentis advances GelrinC(R) toward commercialization in Europe following CE Mark approval and continues its pivotal […]
InvestorNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Expands U.S. Clinical Site Network for Phase III GelrinC(R) Trial
January 29, 2026
Regentis Biomaterials (NYSE American: RGNT) announced the expansion of its U.S. clinical site network to support its ongoing pivotal Phase III study of GelrinC(R) for knee cartilage repair and future clinical programs. The expanded network includes leading academic and orthopedic institutions across the United States, including NYU Langone Orthopedic & Sports Medicine, The Ohio State […]
InvestorNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Reports Long-Term GelrinC(R) Imaging Data Demonstrating Native-Like Cartilage Regeneration
January 20, 2026
Regentis Biomaterials (NYSE American: RGNT) announced new long-term imaging data from its completed European clinical trial of GelrinC(R), showing regenerated cartilage with internal structural organization closely resembling healthy native hyaline cartilage. Published in the peer-reviewed journal Cartilage, the MRI-based analysis demonstrated progressive tissue maturation over 24 months, with repaired cartilage exhibiting layered architecture comparable to […]
InvestorNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Reports Long-Term Phase II GelrinC(R) Cartilage Repair Results Published in Cartilage Journal
January 6, 2026
Regentis Biomaterials (NYSE American: RGNT) today announced publication of long-term follow-up results from its completed Phase II clinical trial of GelrinC(R) in the peer-reviewed journal Cartilage, highlighting durable cartilage regeneration at 24 months. The study reported a mean MOCART score of 88.8 out of 100 across all lesions, with osteochondral lesions achieving a mean score […]
InvestorNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Secures New U.S. Patent for GelrinC Liquid Formulation
January 5, 2026
Regentis Biomaterials (NYSE American: RGNT) announced that the U.S. Patent and Trademark Office has issued the company a new patent titled “Organic Solvent Free Compositions Comprising Protein-Polymer Conjugates and Uses Thereof,” covering a liquid, ready-to-use formulation of its lead product, GelrinC(R), as well as improved production processes that eliminate the use of organic solvents. The […]